CSI Market
Sign In | Register

Halozyme Therapeutics Inc (HALO) Quarterly Balance Sheets

Quarterly · GAAP · USD millions
Access HALO Annual Balance Sheets →
Changes in quarterly balance sheet trends offer perspective on how Halozyme Therapeutics Inc balances growth, leverage, and shareholder equity.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/HALO/balance-sheets
https://api.csimarket.com/api/v1/companies/HALO/fundamentals
https://api.csimarket.com/api/v1/companies/HALO/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API
Balance Sheet API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery
Connect Your AI Assistant
How to Connect Your AI Assistant to CSIMarket MCP MCP Server
Access this full dataset via API
Free sample Full docs All endpoints
Quarterly Report, GAAP in USD millions
ITEM 		(Sep 30 2026)
(Jun 30 2026) (Mar 31 2026) (Dec 31 2025) (Sep 30 2025)
Assets
Cash & cash equivalent1,029.99
Available-for-sale Securities, Debt Securities, Current MA44.49
Cash & Short-term Investments1,073.00
Accounts receivable518.59
Inventories132.61
Derivatives, Collateral, Regulatory, Deferred1.90
Other Current Assets0.00
Prepaid Expense And Other Assets Current0.00
Total Current Assets1,846.73
Equipment/Property/Plant Net87.15
Goodwill net581.73
Intangible Assets892.93
Long-term investments0.86
Financial Instruments6.00
Deferred, Prepaid and Other Assets, Noncurrent182.94
Other Assets, Noncurrent0.00
Debt Securities Available For Sale Excluding Accrued Interest Current8.87
Accounts Receivable And Contract With Customer Asset After Allowance For Credit Loss Current457.99
Prepaid Expense And Other Assets Noncurrent50.92
Total Assets3,473.35
Liabilities
Accounts Payable, Current AC33.55
Accrued Liabilities, Current AC136.93
Financial Instruments1.40
Long-term Debt, Current Maturities LO305.61
Taxes Payable28.69
Total Current Liabilities476.09
Long-term debt2,944.69
Total Long-term Debt2,944.69
Financial Instruments, Insurance, Noncurrent2.90
Other liabilities, Noncurrent104.91
Total Liabilities3,528.59
Stockholders' Equity
Common Stock Value0.11
Additional Paid In Capital Common Stock0.00
Retained Earnings / Accumulated Deficit-58.13
Accumulated Other Comprehensive Income2.78
Other Equity2.78
Common Stockholder's Equity-55.24
Total Stockholder's Equity-55.24
Liabilities & Stockholder's Equity3,473.35
4 historic quarters locked

Sign in to unlock the full Halozyme Therapeutics Inc balance sheet history.

Sign In Create Free Account

About Halozyme Therapeutics Inc Quarterly Balance Sheet

What this statement shows

This page presents issuer-reported balance sheet data, detailing assets, liabilities, and stockholders equity as reported in SEC 10-Q filings and standardized by CSIMarket. The balance sheet reflects the company's financial position at the end of each reporting period.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - balance-sheet normalization in the CSIMarket.com financial database.
  • Accession: 0001159036-26-000145

Balance sheet figures represent financial position at specific reporting dates and may be revised in subsequent filings.

Get the full CSIMarket dataset: Subscribe API Connect Your AI